Vertex Pharmaceuticals Incorporated

WBAG:VRTX Stock Report

Market Cap: €95.5b

Vertex Pharmaceuticals Valuation

Is VRTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VRTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: VRTX (€369.25) is trading below our estimate of fair value (€639.86)

Significantly Below Fair Value: VRTX is trading below fair value by more than 20%.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VRTX?

Other financial metrics that can be useful for relative valuation.

VRTX key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue9.1x
Enterprise Value/EBITDA20x
PEG Ratio2.5x

Price to Earnings Ratio vs Peers

How does VRTX's PE Ratio compare to its peers?

The above table shows the PE ratio for VRTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.8x
CSL CSL
35.3x14.7%AU$133.7b
REGN Regeneron Pharmaceuticals
24.4x11.2%US$95.3b
GILD Gilead Sciences
169.5x35.8%US$81.6b
AMGN Amgen
22.1x9.0%US$144.8b
VRTX Vertex Pharmaceuticals
28.3x11.5%€102.4b

Price-To-Earnings vs Peers: VRTX is good value based on its Price-To-Earnings Ratio (28.3x) compared to the peer average (62.8x).


Price to Earnings Ratio vs Industry

How does VRTX's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a31.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: VRTX is good value based on its Price-To-Earnings Ratio (28.3x) compared to the European Biotechs industry average (30.8x).


Price to Earnings Ratio vs Fair Ratio

What is VRTX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VRTX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate VRTX's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VRTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€369.25
€428.55
+16.1%
12.2%€535.08€302.97n/a29
Apr ’25€388.20
€429.29
+10.6%
12.4%€534.39€302.58n/a29
Mar ’25€396.70
€425.42
+7.2%
12.6%€532.92€299.65n/a28
Feb ’25€399.20
€401.70
+0.6%
13.9%€514.28€288.88n/a27
Jan ’25€371.65
€371.73
+0.02%
11.0%€454.00€285.11n/a28
Dec ’24€326.90
€363.95
+11.3%
9.2%€419.20€288.66n/a28
Nov ’24€347.60
€366.12
+5.3%
9.4%€431.51€297.14n/a28
Oct ’24€332.80
€363.65
+9.3%
9.3%€431.33€297.01n/a27
Sep ’24€326.25
€355.56
+9.0%
9.4%€421.94€290.54n/a27
Aug ’24€318.60
€345.82
+8.5%
9.9%€415.19€278.61n/a27
Jul ’24€322.20
€343.89
+6.7%
9.3%€417.88€280.42n/a27
Jun ’24€298.30
€346.87
+16.3%
10.0%€425.04€284.29n/a28
May ’24€309.80
€307.38
-0.8%
9.5%€400.15€255.22n/a26
Apr ’24€287.95
€310.19
+7.7%
9.5%€408.50€259.95€388.2026
Mar ’24€272.35
€309.47
+13.6%
9.7%€409.64€260.68€396.7026
Feb ’24€290.50
€303.64
+4.5%
10.3%€405.64€258.13€399.2026
Jan ’24€269.75
€313.61
+16.3%
10.8%€426.23€256.71€371.6525
Dec ’23€304.90
€313.61
+2.9%
10.8%€426.23€256.71€326.9025
Nov ’23€319.40
€325.97
+2.1%
10.8%€447.48€268.29€347.6025
Oct ’23€298.50
€311.55
+4.4%
10.9%€390.95€251.25€332.8025
Sep ’23€288.35
€304.96
+5.8%
10.9%€382.58€245.88€326.2525
Aug ’23€270.50
€296.03
+9.4%
12.1%€360.53€235.13€318.6024
Jul ’23€272.80
€282.63
+3.6%
12.2%€353.50€230.54€322.2023
Jun ’23€251.10
€275.95
+9.9%
12.2%€345.40€225.26€298.3023
May ’23€262.45
€273.58
+4.2%
12.4%€331.59€210.32€309.8022
Apr ’23€240.20
€248.89
+3.6%
10.9%€308.78€188.34€287.9522

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.